Intuitive Surgical's investment case balances durable growth against mounting margin and placement risks. Revenues rose 18.5% year over year to $2.89 billion, driven by a 16% increase in worldwide procedures across da Vinci and Ion, with Ion procedures surging 36%. The company placed 468 da Vinci systems, including 246 da Vinci 5 systems, and 55 Ion systems, while its cash and investments reached $8.63 billion. However, adjusted gross margin guidance of 68-69% for 2026 includes an estimated 1% tariff impact on revenues, and second-quarter adjusted gross margin would have been 68.7% excluding a $36 million tariff refund. U.S. da Vinci procedure growth slowed to 12%, bariatric procedures declined at a high-single-digit rate amid greater GLP-1 use, and about half of U.S. da Vinci placements were trade-ins, with leasing representing 54% of total placements. China and parts of Europe face government budget constraints and policy-driven pricing pressure.
Intuitive Surgical IncWorldwide procedures rose 16% and Ion procedures surged 36%, driving 18.5% revenue growth.
Medtronic PLC
Johnson & Johnson